NEW YORK (
) hit a new 52-week high Monday as it is currently trading at $11.45, above its previous 52-week high of $11.36 with 2.6 million shares traded as of 2:15 p.m. ET. Average volume has been 999,100 shares over the past 30 days.
Spectrum has a market cap of $470.7 million and is part of the
industry. Shares are up 41.2% year to date as of the close of trading on Friday.
Spectrum Pharmaceuticals, Inc., a commercial-stage biotechnology company, primarily focuses on oncology and hematology. The company engages in acquiring, developing, and commercializing a broad and diverse pipeline of late-stage clinical and commercial products. The company has a P/E ratio of 25.7, above the average drugs industry P/E ratio of 25.4 and above the S&P 500 P/E ratio of 17.7.
- Practice your SPPI trading strategies and win cash in our stock game.
TheStreet Ratings rates Spectrum as a
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we find that the growth in the company's earnings per share has not been good. You can view the full
52-week high stocks
or get investment ideas from our